IP Library Granted Patent US 12,376,623
Granted Patent B2
US 12,376,623 · App. 17/420,637 · Granted Aug 5, 2025

Aerosol generation

Inventors: Walid Abi Aoun (London, GB); David Bishop (London, GB)
Assignee: NICOVENTURES TRADING LIMITED
A24F40/46A24B15/167A24F40/10A24F40/30A24F40/42
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,376,623
App. No.
17/420,637
Granted
Aug 5, 2025
Kind
B2
Abstract

A device for generating an inhalable medium, the device comprising: a container retaining a first volatilizable material, the material having a pH of greater than 7; a heater for volatilising the first volatilizable material held in the container; a chamber containing aerosolizable material comprising nicotine; and an outlet; the arrangement being such that in use, the first volatilizable material is volatilized by the heater to form a vapor and/or an aerosol, which passes through the chamber containing aerosolizable material and entrains one or more constituents of the aerosolizable material, thereby forming an inhalable medium which passes through the outlet.

Claims (33)

1. A device for generating an inhalable medium, the device comprising:

a container retaining a first volatilizable material that does not contain nicotine, the first volatilizable material having a pH of greater than 7;

a heater for volatilizing the first volatilizable material held in the container;

a chamber containing aerosolizable material comprising nicotine; and

an outlet;

the arrangement being such that in use, the first volatilizable material is volatilized by the heater to form a vapor and/or an aerosol, which passes through the chamber containing aerosolizable material and entrains one or more constituents of the aerosolizable material, thereby forming an inhalable medium which passes through the outlet.

2. The device according to claim 1 , wherein the first volatilizable material comprises a liquid or gel.

3. The device according to claim 1 , wherein the first volatilizable material comprises sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium hydrogen carbonate, potassium hydrogen carbonate, sodium carbonate, potassium carbonate, calcium carbonate or mixtures thereof, or other soluble bases.

4. A cartridge for use in a device for generating an inhalable medium, the cartridge comprising (i) a first volatilizable material that does not contain nicotine in a container, the first volatilizable material having a pH of greater than 7, and (ii) an aerosolizable material comprising nicotine in a chamber, the cartridge being configured such that in use, a vapor and/or an aerosol generated from the first volatilizable material passes through the chamber containing an aerosolizable material and entrains one or more constituents of the aerosolizable material.

5. The cartridge according to claim 4 , wherein the first volatilizable material comprises a liquid or gel.

6. The cartridge according to claim 4 , wherein the first volatilizable material comprises sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium hydrogen carbonate, potassium hydrogen carbonate, sodium carbonate, potassium carbonate, calcium carbonate or mixtures thereof, or other soluble bases.

7. A kit comprising;

(i) a first pod containing a first volatilizable material that does not contain nicotine, wherein the first volatilizable material has a pH of greater than 7; and

a second pod containing an aerosolizable material comprising nicotine;

wherein the first and second pods are configured for use in a device such that in use, a vapor and/or an aerosol generated from the first volatilizable material passes through the aerosolizable material and entrains one or more constituents of the aerosolizable material.

8. The kit according to claim 7 , wherein the first volatilizable material is a liquid or gel.

9. The kit according to claim 7 , further comprising a device for use in generating an inhalable medium, wherein the device comprises a heater.

10. The kit according to claim 9 , wherein the heater in the device is configured to volatilize the first volatilizable material in use.

11. A method of generating an inhalable medium comprising;

volatilizing a first volatilizable material that does not contain nicotine and having a pH of greater than 7 to form a vapor and/or an aerosol;

contacting the vapor and/or aerosol with an aerosolizable material comprising nicotine, resulting in the release of nicotine from the aerosolizable material, and the entraining of one or more constituents of the aerosolizable material in the vapor and/or aerosol.

12. The method of claim 11 , wherein the first volatilizable material comprises sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium hydrogen carbonate, potassium hydrogen carbonate, sodium carbonate, potassium carbonate, calcium carbonate or mixtures thereof, or other soluble bases.

13. A method of providing sustained release of nicotine from a device for generating an inhalable medium, the device comprising;

a container retaining a first volatilizable material that does not contain nicotine, the first volatilizable material having a pH of greater than 7;

a heater for volatilizing the first volatilizable material held in the container;

a chamber containing an aerosolizable material comprising nicotine; and

an outlet;

the method comprising volatilizing the first volatilizable material with the heater to form a vapor and/or aerosol and contacting the vapor and/or aerosol with the aerosolizable material in order to liberate nicotine from the aerosolizable material.

14. The method of claim 11 , wherein the vapor and/or aerosol formed from the first volatilizable material has a pH of greater than 7 , and wherein the vapour and/or aerosol is used to pH-treat the aerosolizable material comprising nicotine.

15. The method of claim 14 , wherein the vapor and/or aerosol formed from the first volatilizable material is contacted with the aerosolizable material, resulting in the release of nicotine from the aerosolizable material, and the entraining of one or more constituents of the aerosolizable material in the vapor and/or aerosol.

16. The method of claim 13 , wherein the vapor and/or aerosol formed from the first volatilizable material has a pH of greater than 7, and wherein the vapour and/or aerosol is used to pH-treat the aerosolizable material comprising nicotine.

17. The method of claim 16 , wherein the vapor and/or aerosol formed from the first volatilizable material is contacted with the aerosolizable material, resulting in the release of nicotine from the aerosolizable material, and the entraining of one or more constituents of the aerosolizable material in the vapor and/or aerosol.

18. The method of claim 13 , wherein the first volatilizable material comprises sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium hydrogen carbonate, potassium hydrogen carbonate, sodium carbonate, potassium carbonate, calcium carbonate or mixtures thereof, or other soluble bases.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 27, 2022
From: ABI AOUN, WALID; BISHOP, DAVID
To: NICOVENTURES TRADING LIMITED
Reel/Frame 058788/0445 →
Priority Claims (1)
GB 1900126 · Jan 4, 2019 · national
Continuity (1)
Related Publication 20220079236A1 · Mar 17, 2022
References Cited (31)
US 4284089A · Ray · 1981 [cited by applicant]
US 5105834A · Saintsing et al. · 1992 [cited by applicant]
US 6095558A · Bayer · 2000 [cited by examiner]
US 9668521B2 · Kuczaj · 2017 [cited by examiner]
US 10375996B2 · Aoun · 2019 [cited by examiner]
US 10426199B2 · Turner · 2019 [cited by examiner]
US 10660365B2 · Lipowicz · 2020 [cited by examiner]
US 10758686B2 · Reevell · 2020 [cited by examiner]
US 10857316B2 · Marks · 2020 [cited by examiner]
US 11083224B2 · Lin · 2021 [cited by examiner]
US 11324254B2 · Aoun · 2022 [cited by examiner]
US 11511056B2 · Hepworth · 2022 [cited by examiner]
US 11589617B2 · Yilmaz · 2023 [cited by examiner]
US 11672276B2 · Yilmaz · 2023 [cited by examiner]
US 11865246B2 · Hepworth · 2024 [cited by examiner]
US 20120006342A1 · Rose et al. · 2012 [cited by applicant]
US 20160205992A1 · Bell et al. · 2016 [cited by applicant]
US 20170251727A1 · Nielsen · 2017 [cited by applicant]
US 20170319799A1 · Yamada et al. · 2017 [cited by applicant]
US 20180279666A1 · Aoun et al. · 2018 [cited by applicant]
US 20180279667A1 · McAdam et al. · 2018 [cited by applicant]
EP 3251529 · 2017 [cited by applicant]
JP 2018201514A · 2018 [cited by applicant]
KR 20180111460 · 2018 [cited by applicant]
WO 2011034723A1 · 2011 [cited by applicant]
WO 2016050244A1 · 2016 [cited by applicant]
WO 2016062777A1 · 2016 [cited by applicant]
WO 2016079729A1 · 2016 [cited by applicant]
WO 2018033649A1 · 2018 [cited by applicant]
WO 2018210681A2 · 2018 [cited by applicant]
International Search Report and Written Opinion for PCT/EP2019/086691 date mailed Apr. 14, 2020. [cited by applicant]